NovaBridge Biosciences (NBP)

NovaBridge Biosciences (NBP) Healthcare & Pipeline Overview

NovaBridge Biosciences is a clinical-stage biotech firm specializing in immuno-oncology agents for cancer treatment in the U.S. With a pipeline featuring bispecific and neutralizing antibodies, NovaBridge collaborates with industry leaders like Bristol Myers Squibb and ABL Bio, positioning itself in the competitive biotechnology landscape.

What Is the Investment Thesis for NBP?

NovaBridge Biosciences presents a notable research candidate within the immuno-oncology space. The company's pipeline of bispecific and neutralizing antibodies, particularly givastomig (Phase 1b for gastric cancer) and ragistomig (Phase 1 for solid tumors), offers significant potential for future revenue streams. Strategic collaborations with established players like Bristol Myers Squibb and ABL Bio validate the company's technology and provide access to resources and expertise. However, the company's success hinges on the successful completion of clinical trials and regulatory approvals, which are subject to inherent risks. With a market cap of $232.26M and a beta of 1.74, NovaBridge exhibits moderate volatility. Investors should carefully consider the risks associated with clinical-stage biotech companies before investing.

Based on FMP financials and quantitative analysis

NBP Key Highlights

• NovaBridge Biosciences is focused on immuno-oncology, a rapidly growing area in cancer treatment.
• The company has multiple drug candidates in clinical trials, including givastomig in Phase 1b for gastric cancer.
• Strategic collaborations with companies like Bristol Myers Squibb and ABL Bio validate NovaBridge's technology and provide access to resources.
• NovaBridge Biosciences changed its name from I-Mab in October 2025, reflecting a strategic shift or rebranding effort.
• The company has a market capitalization of $232.26M, indicating its size and relative value in the market.

Who Are NBP's Competitors?

NBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NBP's Key Strengths?

• Innovative pipeline of bispecific and neutralizing antibodies
• Strategic collaborations with established pharmaceutical companies
• Experienced management team with expertise in immuno-oncology
• Focus on a high-growth area of cancer treatment

What Are NBP's Weaknesses?

• Limited financial resources compared to larger pharmaceutical companies
• Dependence on clinical trial outcomes and regulatory approvals
• Early-stage pipeline with significant development risk
• Small number of employees

What Could Drive NBP Stock Higher?

• Phase 1b clinical trial results for givastomig in gastric cancer.
• Phase 1 clinical trial results for ragistomig in solid tumors.
• Advancement of uliledlimab through preclinical and clinical development.
• Expansion of strategic collaborations with pharmaceutical companies.
• Potential for breakthrough therapy designations from regulatory agencies.

What Are the Key Risks for NBP?

• Negative return on equity (-0.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for drug candidates.
• Regulatory setbacks or delays in drug approvals.
• Competition from other companies in the immuno-oncology space.
• Dependence on funding and strategic partnerships.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for NBP?

• Expansion into New Therapeutic Areas: NovaBridge has the opportunity to expand its pipeline beyond gastric and solid tumors into other cancer types. By leveraging its expertise in bispecific and neutralizing antibodies, the company can target new oncology indications with unmet medical needs. This expansion could significantly increase NovaBridge's market potential and revenue streams, with the global oncology market projected to reach trillions of dollars by 2030.
• Geographic Expansion: Currently focused on the United States, NovaBridge can pursue geographic expansion into other markets, such as Europe and Asia. These regions offer significant growth opportunities due to their large populations and increasing healthcare spending. Entering new markets would require regulatory approvals and strategic partnerships, but it could substantially increase NovaBridge's global reach and revenue.
• Strategic Acquisitions: NovaBridge could pursue strategic acquisitions of other biotech companies or technologies to expand its pipeline and capabilities. Acquiring complementary assets would allow NovaBridge to accelerate its drug development programs and diversify its portfolio. This strategy could enhance NovaBridge's competitive position and create synergies that drive long-term growth.
• Advancement of Clinical Trials: The successful advancement of givastomig, uliledlimab, and ragistomig through clinical trials represents a significant growth opportunity for NovaBridge. Positive clinical trial results would validate the efficacy and safety of these drug candidates, increasing their commercial potential and attracting potential partners. The company's Phase 1b trial for givastomig in gastric cancer is a key milestone to watch.
• Partnerships and Licensing Agreements: NovaBridge can continue to pursue partnerships and licensing agreements with larger pharmaceutical companies to co-develop and commercialize its drug candidates. These collaborations provide access to funding, expertise, and distribution networks, accelerating the development and commercialization process. The existing partnerships with Bristol Myers Squibb, ABL Bio, and Ferring International Center SA demonstrate NovaBridge's ability to attract and maintain strategic alliances.

What Opportunities Does NBP Have?

• Expansion into new therapeutic areas and geographic markets
• Potential for breakthrough therapies in cancer treatment
• Increased demand for immuno-oncology agents
• Strategic acquisitions of complementary technologies or companies

What Threats Does NBP Face?

• Competition from larger pharmaceutical companies with more resources
• Failure of clinical trials or regulatory setbacks
• Patent expirations and generic competition
• Changes in healthcare regulations or reimbursement policies

What Are NBP's Competitive Advantages?

• Proprietary technology in bispecific and neutralizing antibodies.
• Strong intellectual property portfolio protecting drug candidates.
• Established collaborations with leading pharmaceutical companies.
• Expertise in immuno-oncology drug development and clinical trials.

What Does NBP Do?

Founded in 2014 and headquartered in Rockville, Maryland, NovaBridge Biosciences (formerly I-Mab, renamed in October 2025) is a biotechnology company dedicated to the discovery, development, and commercialization of innovative immuno-oncology therapies. The company's primary focus is on developing novel agents for the treatment of various cancers. NovaBridge's pipeline includes several promising drug candidates, such as givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer. Additionally, they are developing uliledlimab, a CD73 neutralizing antibody, and ragistomig, another bispecific antibody in Phase 1 clinical trials for solid tumors. NovaBridge has established strategic collaborations to advance its research and development efforts. These include a licensing agreement with Ferring International Center SA for FE301, an interleukin-6 inhibitor, and collaborations with Bristol Myers Squibb for givastomig, ABL Bio, Inc. for givastomig and ragistomig, and TJ Bio for uliledlimab. These partnerships underscore NovaBridge's commitment to innovation and its ability to leverage external expertise to accelerate drug development.

What Products and Services Does NBP Offer?

• Develop immuno-oncology agents for cancer treatment.
• Research and develop bispecific antibodies.
• Research and develop neutralizing antibodies.
• Conduct Phase 1b clinical trials for gastric cancer treatment.
• Conduct Phase 1 clinical trials for solid tumor treatment.
• Collaborate with pharmaceutical companies for drug development.
• Engage in strategic licensing agreements for drug candidates.

How Does NBP Make Money?

• Develop and out-license novel immuno-oncology therapeutics.
• Collaborate with larger pharmaceutical companies for co-development and commercialization.
• Generate revenue through licensing fees, milestone payments, and royalties.
• Focus on early-stage clinical development to increase asset value.

What Industry Does NBP Operate In?

NovaBridge Biosciences operates within the competitive biotechnology industry, specifically focusing on immuno-oncology. This sector is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The global immuno-oncology market is projected to reach billions of dollars by 2030, driven by the increasing prevalence of cancer and advancements in immunotherapy. NovaBridge competes with both large pharmaceutical companies and smaller biotech firms in the development of novel cancer therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.

Who Are NBP's Key Customers?

• Patients with cancer who may benefit from novel immuno-oncology therapies.
• Pharmaceutical companies seeking to expand their oncology portfolios through licensing or acquisition.
• Healthcare providers who prescribe and administer cancer treatments.
• Research institutions and academic centers involved in clinical trials.

NBP Valuation & Market Position

With a $232.26M market cap, NovaBridge Biosciences sits in the micro-cap segment of the market. Relative to its peer group, NBP's quantitative score of 58/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project NovaBridge Biosciences revenue of about $0 for fiscal 2026, with EPS near $-3.29.

F-Score 2/9Financial Health

NovaBridge Biosciences's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE -1%Key Financial Metrics

Return on equity for NovaBridge Biosciences stands at -0.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -53.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.

NBP Financials

NBP Latest News

NBP Analyst Consensus

NBP MoonshotScore

Common Questions About NBP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources